Fig. 2

Lenalidomide decreases proliferation and reduces IRF4 expression in ATLL. a Resazurin proliferation assay of cells treated for 2 days with varying doses of lenalidomide normalized to cells treated with DMSO control. Two-tailed T-tests of each dose compared to DMSO were conducted for each cell line. b Resazurin proliferation assay at 8 days post-treatment with 2.5 μM lenalidomide. Two-tailed T-tests were conducted for each cell line compared to Hut78 control T-cells. c Dose response curves at 4 days post-treatment. IC50s were calculated with Prism Graphpad software. d Proliferation time course of cells treated with 1 μM lenalidomide. e Western blot of cells treated for 24 h with 10 and 20 μM lenalidomide. Bands were quantified using BioRad software and presented values are normalized to actin